Phaseline

Targets › FGB

FGB (Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 4, 1 Phase 3; Other; next expected readout Dec 2026.

Cleaved by the protease thrombin to yield monomers which, together with fibrinogen alpha (FGA) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function in hemostasis as one of the primary components of blood clots. (UniProt, P02675)

Open in Phaseline: the race on FGB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Trauma Hemostatis and Oxygenation Research (THOR) NetworkIntercept Fibrinogen Complex (IFC)
Pathogen-reduced cryoprecipitated fibrinogen complex containing fibrinogen, Factor XIII, a
FGBPhase 4Liver Transplant SurgeryMar 2028
Corza MedicalFibrinogen, Human
Fibrinogen exogenous protein
FGA, FGB, FGGPhase 3HemorrhageDec 2026

Conditions

Liver Transplant Surgery (1) Hemorrhage (1)

Modalities

mixed (2)

Companies

Trauma Hemostatis and Oxygenation Research (THOR) Network (1) Corza Medical (1)

Related targets

FGA (1) FGG (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.